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Abstract
Introduction: Diabetes mellitus (DM) is a common disease with a highly significant burden among 
the Saudi population. This study aimed to investigate the effects of adding either magnetic or laser 
therapy to medications in patients with diabetic peripheral neuropathy (DPN). 
Methods: Seventy-one medically controlled diabetic patients were randomly assigned to 1) Magnetic 
group: 26 patients were exposed to magnetic therapy for 20 minutes/session, 2 sessions/week, for 
3 months 2) Laser group: 25 patients were exposed to laser therapy with intensity 5.7 J/cm2 for 30 
minutes/session, 2 times/week, for 3 months. 3) Drug group: 20 patients received only the regular 
medications for diabetic control and pain analgesia. Pain and neuropathy were assessed by the 
visual analog scale (VAS) and the Toronto Clinical Neuropath Scoring System (TRCNSS). Conduction 
velocities and amplitudes of peroneal and sural nerves were measured by electromyography. 
Results: The results showed significant increases in conduction velocities and amplitudes in both 
magnetic and laser groups in parallel with significant reductions in TRCNSS. Non-significant changes 
were obtained only after using only medications (P > 0.05). The mean values of VAS reduced 
significantly in the three groups. The least significant differences showed significant changes among 
the three groups, whereas non-significant differences were obtained between both magnetic and 
laser groups. 
Conclusion: There were non-significant differences between both magnetic and laser therapy groups. 
Addition of either magnetic or laser therapy to medications could bring extra positive benefits 
to patients with DPN. Both magnetic and laser therapy can be applied with medications for the 
treatment of patients with DPN.
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Introduction
Diabetes mellitus (DM) is a common disease which is 
accompanied by a highly significant social and economic 
burden.1 Diabetes has high prevalence and progressive 
rates among the Saudi population. It is strongly 
associated with both microvascular and macrovascular 
complications such as retinopathy, neuropathy, and 
cardiovascular diseases.2 Peripheral neuropathy is the 
most common complication of diabetic patients.3 Diabetic 
peripheral neuropathy (DPN) is commonly associated 
with a high rate of patients’ mortality and morbidity.4 The 
prevalence and progression of DPN increase in parallel 
with the chronicity of diabetes, poor glycemic control and 
pre-existing cardiovascular risk factors.3 DPN is usually 
characterized by increases in pain severity, impairments 
in tactile and proprioceptive sensation, vibration sense, 
and improper postural control.5 Distal symmetric 
polyneuropathy is the commonest form of diabetic 
neuropathy.6
Nevertheless, diagnostic methods of neuropathy are 
diverse. The highest sensitive and objective method is 
the conduction velocity test (CVT).6 Diagnosis of DPN 
is confirmed when the symptoms and signs of peripheral 
nerve dysfunctions are present after the exclusion of all 
other causes.3 Comprehensive evaluation of DPN also 
requires careful examination of the lower extremity with 
validated clinical tests such as light touch, vibration, 
and the Toronto Clinical Neuropathy Scoring System 
(TRCNSS) which is one of the most sensitive clinical 
scales to detect early neuropathies.7 
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To date, although one-third of diabetic patients are 
affected with neuropathic pain, its treatment is still 
very complex.6 The focus of management is usually on 
disease modifications and the relief of symptomatic 
pain. Up till now, no specific treatment has been able to 
completely prevent or reverse the progression of DPN.6 
As hyperglycemia is the essential contributing factor in 
DPN, proper glycemic control is the main therapeutic 
target for its treatment.8 Neuropathy happened because 
of reductions in the nerve blood flow and increases in 
nerve hypoxia, thus vasodilating drugs as prostaglandin 
analogues are usually beneficial in the treatment of 
neuropathic pain.4,9 Although many drugs have been 
used for the treatment of DPN, their roles are still 
unconfirmed.10 The administration of analgesics as 
tricyclic anti-depressants and topical agents may be 
effective but with limited success and unsatisfactory 
results.11 However, around half of the patients with 
DPN have shown adequate symptomatic pain relief in 
association with frequent side effects such as drowsiness, 
lethargy and unsteadiness.11 In addition, these analgesics 
do not stop or delay the progression of the underlying 
pathological neuropathic changes.12 
Physical therapy can actively relieve the signs and 
symptoms of DPN. Active exercises have had many 
benefits for diabetic patients.1,3,5,8 At the same time, there 
are limitations for many diabetic patients to practice 
physical exercise, which enforce us to seek other alternative 
therapeutic modalities for diabetic neuropathic pain.1 
Magnetic and laser therapy are recent interventions that 
may enhance the treatment of DPN.13,14 
Pulsed electro-magnetic therapy (PEMT) was applied 
mostly to animals in experimental studies.15 The 
application of PEMT for 12 consecutive days for 30 
minutes relieved neuropathic pain and increased nerve 
conduction velocity.16 In general, PEMT is considered safe 
and supplemental therapy for DPN.17 Unfortunately, there 
are still contradictions about the benefits of magnetic 
therapy despite its wide uses on diabetic patients.15,16,18 
The application of PEMT for 20 minutes/session for 3 
weeks resulted in a non-significant improvement in pain 
intensity and sleep conditions of patients with DPN.18 
The properly used parameters for the clinical application 
of PEMT are also still controversial.14 Its limited uses on 
human beings aroused our enthusiasm for increasing 
applied studies into the effects of magnetic therapy on 
human beings.15 
Low-level laser therapy (LLLT) is generally and safely 
applied to many patients with co-morbid diseases.19,20 
There is an unambiguous piece of evidence that LLLT 
with different wavelengths has different effects on the 
cellular level.21 It was previously applied for 1 minute/
site on 4 para-vertebral points in the lumbosacral spine, 
3 points on the ischial region, and 2 points on the dorsum 
of the foot. 21 Also, LLLT has been applied on 6 para-spinal 
points (L4-S1) to irradiate along the output of the right 
and left sciatic nerve.22 Despite a wide range of LLLT 
uses in a clinical setting, there is non-sufficient evidence 
to confirm its effects on neuropathic pain in humans.23 
Some authors suggested its usage as a new therapeutic 
modality for patients with DPN.24 and others proved that 
LLLT has been effective in the repair of nerve damage.25 
However, objective clinical studies have failed to detect 
the exact benefits of laser therapy on DPN.26 Furthermore, 
up till now, there have been controversies over the effects 
and proper parameters of laser application techniques 
that can be used for the treatment of DPN to prevent 
unnecessary sufferings and to reduce direct and indirect 
costs to those patients and their families.20 There is still a 
need for more randomized controlled trials on physical 
therapy advanced modalities for the treatment of patients 
with DPN.23 Therefore, the objective of the current study 
was to investigate the effects of adding either magnetic or 
laser therapy to drug therapy in patients with DPN and to 
compare them.
Materials and Methods 
Subjects
Nineteen type-II diabetic patients with peripheral 
neuropathy were enrolled in this study after screening 
by specialized physician (Figure 1). The patients’ 
demographic data, including age, sex, the duration of 
diabetic history and beginning of neuropathy, the body 
mass index, fasting blood glucose (FBG), and the used 
medications are shown in Table 1. 
Inclusion criteria: Patients (male and female) with 
painful DPN lasted > 6 months. Their age ranged from 35 
to 70 years. Patients have sensory abnormalities, burning 
pain with paresthesia in both lower extremities,4,27 
impaired sensory and/or motor conduction velocity 
(MCV) in a minimum one nerve of the lower limbs.13 All 
patients were medically controlled. The usage of analgesic 
medications such as anti-depressants and anticonvulsants 
could be received without any change for at least 4 
weeks prior to recruitment and during the study.4,6 A 
consent form was signed by all the patients prior to their 
participation. They were informed that the collected data 
would be published.
Exclusion criteria: The patients were excluded if they 
had DPN from other causes than diabetes, lack of blood 
sugar control, vascular insufficiency, other neurological 
impairments, uncontrolled medical conditions (e.g. 
tumors and thyroid dysfunctions), pregnancy, metallic 
implantation, drug abuse, and a TRNCSS total score 
<5.4,7,8,27,28
Treatment Equipment
1- BEMER mattress: BEMER International AG 
(Liechtenstein) mattress product was used for producing 
magnetic therapy. The maximum average flux density 
(intensity) of BEMER on its highest output level is 150 
microtesla (μT). The B. BOX Professional control units 
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had 3 pre-stored programs with different intensity and 
treatment times. 29
2- The Laser Scanner device (ASA Com. srl, Arcugnano, 
Italy): It emits a mixed light of both the He-Ne continuous 
wavelength of 850 nanometers (nm) and the pulsed 
infrared laser with the wavelength 905 nm. The device 
had maximum power of 10 watt (W). The output density 




The following measures were employed for all recruited 
patients by a blinded investigator.
a. Fasting Blood Glucose
A venous fasting blood sample was drawn from the 
anti-cubital vein to detect the blood glucose level (pre-
intervention, after 6 weeks and at the end of treatment) 
for all patients.28
b. Electrophysiological Test
MCV of the peroneal nerve and sensory conduction 
velocity (SCV) of the sural nerve in addition its amplitudes 
were measured by a neuro-consultant.22,28 The patients 
with conduction velocity from 33-48 meter/second were 
Table 1. Demographic Data of Recruited Patients
Variables
Magnetic Group Laser Group Drug Group
F Value P Value
Mean ± SD Mean ± SD Mean ± SD
Age (y) 60.31 ± 9.82 58.88 ± 12.15 54.05 ±10.69 1.971 0.147
BMI, kg/ m2 27.32 ± 1.75 28.17 ± 1.97 27.79 ± 1.46 1.493 0.232
Sex, No. (%) 0.209 0.812
Males 18 (69.3) 16 (64) 12 -- (60)
Females 8 (30.7) 9 (36) 8 -- (40)
Duration of incidence of diabetes (y) 16.31 ±7.61 18.8 ±7.58 13.65 ± 6.71 2.726 0.073
Duration of beginning of diabetic neuropathy (y) 4.11 ±2.55 5.0 ±2.71 3.25 ± 2.07 2.767 0.070
Pre-FBG, mg/dL 142.38 ±6.8 140.68 ±6.77 141.5 ± 7.01 0.395 0.675
in-FBG, mg/dL 136.38 ±5.32 136.08 ±4.99 135.85 ±5.16 0.044 0.957
Post-FBG, mg/dL 136.5 ±5.46 136.2 ±5.17 136.6 ±5.19 0.062 0.940
Oral drugs, No. (%) 21 (80.8) 21 (84) 16 (80) 0.142 0.931
Insulin, No. (%) 5 (19.2) 4 (16) 4 (20)
BMI: body mass index; FBG, fasting blood glucose; in-FBG mg/dL: fasting blood glucose after 6 weeks. 
Figure 1. The Flow Diagram of Patients› Recruitment.
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recruited as confirmed DPN. 16,21 All measures were 
performed by using (NicoletTM EDX- Viking version 
20 software Germany) at a controlled temperature of 
25°C.27,28 
1. Peroneal nerve conduction velocity: It was 
investigated by putting standard surface electrodes. The 
distal stimulation was applied at 8 cm near to the active 
pickup electrode, just lateral to the Tibialis Anterior 
Tendon. The ground electrode was put at mid-calf. The 
proximal stimulation was applied just below the head of 
the fibula while the recording electrode was applied over 
the Extensor Digitorum Brevis to get a supra-maximal 
stimulus. 4,22,27 
2. Sural nerve conduction velocity: It was investigated by 
putting an active pick-up electrode posterior and below 
the lateral malleolus. The reference electrode was put at 3 
cm distal to the active electrode and the ground electrode 
was put between the cathode of the stimulator and the 
active pickup electrode. Stimulation was applied slightly 
lateral to the midline in the lower third of the posterior 
aspects of the leg with the cathode distally about 17 cm 
from the active electrode (10-14 cm). 4,8,22,27
c. Neuropathy Severity
It was also evaluated by the TRCNSS which is an objective 
method to detect the presence and intensity of DPN. Total 
scores ranged from 0 (normal) to 19 points (maximum).7
d. Pain
It was measured by VAS which is a valid instrument for 
the determination of perceived pain. Every patient was 
asked to point to his or her pain level ranged from 0 (no 
pain) to 10 (maximal pain). 4,27 
e. Vibration Sense
It was evaluated by using a 128-Hz tuning fork from the 
bony prominence of the big toe. 5 
f. Deep Tendon Reflexes
The ankle and knee reflexes were evaluated from relaxed 
sitting position. 22 
Treatment Procedure 
Only 90 patients were randomly and equally assigned to 
3 treatment groups by an independent blinded research 
assistant who opened sealed envelopes that contained a 
computer-generated randomization card (Figure 1). 
1. Magnetic group: Twenty-six patients received drug 
therapy and they were exposed to magnetic therapy by 
a BEMER mattress (the density of the magnetic field was 
between 35 and 50 μT for 20 minutes/session, 2 sessions/
week, for 3 months. The BEMER mattress was applied 
from a relaxed supine lying position. After connecting the 
appliance to the electrical supply, the action of PEMT was 
adjusted below the affected parts from the lower back to 
the feet. The program 3 was applied to achieve the proper 
treatment for 20 minutes.29
2. Laser group: Twenty-five patients received drug 
therapy and they were exposed to the infrared laser (850 
nm) in the continuous wave mode with the total power 
of 5.7 J/cm2 for 30 minutes /session, 2 times per week, for 
3 months. 4,22,27 Both the plantar surface of the feet and 
the lumbosacral area were treated by laser therapy from a 
comfortable prone lying position . The distance between 
the laser head and the treated area of every patient was 
adjusted at 30 cm. The X-Y dimensions of the lumbo-
sacral area were marked by 4 points, one on the lumbar 2, 
one on the sacral 1, and 2 points laterally to the spine by 
about 2 cm. The plantar surface and the lumbosacral areas 
were cleaned with alcohol (95%). Both areas were exposed 
to laser therapy through a sweeping computerized scan at 
an angle of 30° ± 15°. The power density was 6.3 mW/cm2 
and irradiation time was set to 90 sec/cm2 to achieve the 
total dose of 5.7 J/cm2 through 15 min/site/session. Every 
patient and the physical therapist wore protective glasses 
for protection from the laser beam.4,22,27 
3. Drug group: Twenty patients received only their 
regular drug therapy in the form of anti-diabetic drugs 
(either oral or insulin) and analgesic medications for 
peripheral neuropathic pain, including pregabalin (150 
mg/d-300 mg/d) and B-complex multivitamin (B-100), 
one tablet once or twice daily. 9,14,22 
Statistical Analysis
All measured variables with their output data were 
analyzed by using SPSS software (version 23.0) in the 
form of descriptive and inferential analysis. A repeated 
measures ANOVA was used to evaluate the therapeutic 
effects within each group and among 3 groups. ANOVA 
and Pearson’s chi-square were used to compare 
demographic data of all groups. Statistical significance 
was measured at a P value < 0.05 with a confidence 
interval of 95%. 
Results 
Statistical analysis was applied to seventy-one patients 
who completed this study (Figure 1) as nineteen patients 
dropped out. 
Demographic Characteristics of Recruited Patients
The data were reported by using the percent. The 
Pearson chi-square showed non-significant differences in 
gender and used drugs among the 3 groups. The results 
of ANOVA proved non-significant differences in the 
mean values of age, body mass index (BMI), FBG, the 
duration of diabetes, and the beginning of neuropathy 
among 3 groups prior to the interventions. The baseline 
demographic data were similar among the 3 groups 
except for increases number of participated men than 
women (Table 1). 
Rate of Adherence
The mean values of patients’ adherence of both magnetic 
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and laser groups were 20.85 ± 1.78 and 21.32 ± 1.49, P 
value = 0.309, with the percent of 86.87% and 88.83% 
respectively.
Electro Diagnosis Parameters in the 3 Treatment Groups
The results of the repeated measures ANOVA showed 
measured conduction velocities of the peroneal and 
sural nerves and its amplitudes increased significantly 
after adding either magnetic or laser therapy to drug 
therapy (P < 0.05), whereas non-significant changes were 
obtained only after usage of drug therapy (P > 0.05) (Table 
2; Figures 2 & 3).
Toronto Clinical Neuropath Scoring System and VAS in 
Treatment Groups
The TRCNSS reduced significantly after adding either 
magnetic or laser therapy to drug therapy (P < 0.05), 
whereas non-significant changes were obtained only 
after usage of drug therapy P > 0.05) (Figure 4). The VAS 
reduced significantly after interventions in the 3 treatment 
groups (P < 0.05) (Figure 5).
Comparison Among the 3 Treatment Groups
The repeated measures ANOVA showed significant 
differences in the mean values of MCV, SCV, amplitudes 
and TRCNSS among the 3 groups (P < 0.05). The 
comparison of the least significant difference (LSD) 
by the post hoc test proved that there were significant 
differences in the mean values of measured conduction 
velocities, amplitudes, and TRCNSS between the magnetic 
and drug groups. Also, there were significant differences 
between the laser and drug groups (P < 0.05), whereas 
non-significant differences were obtained between the 
Table 2. Mean Values of Motor Conduction Velocities and Amplitudes of the 
Peroneal Nerve in the Treatment Groups
Treatment Groups Mean SD
Mean 
Square




























MCV m/s: Motor condition velocity in meter per second. 
M -ampl mv: Motor amplitude in millivolt.  
 * Significance P value < 0.05.                               
magnetic and laser groups (P > 0.05) (Table 3). In addition, 
the post hoc test proved that there were non-significant 
differences in the mean values of VAS among the 3 groups 
after the interventions (P > 0.05) (Table 3). 
Discussion 
DPN is a common significant source of diabetic patients’ 
distress.6 Although one-third of diabetic patients are 
affected with neuropathic pain, its treatment is still very 
complex.3 The drugs of diabetic control and neuropathic 
























Figure 2. Mean Values of Sensory Conduction Velocity of the 3 
Groups. 
Figure 3. Mean Values of Sensory Amplitudes of the 3 Groups. 
Figure 4. Mean Values of the Toronto Clinical Neuropath Scoring 
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good control of FBG can postpone or delay the onset of 
neuropathy and its associated symptoms.9,10,12 Thus all 
participated patients primarily and regularly received the 
needed drugs.6,9,12,22 
The current results revealed that adding magnetic 
therapy to drug therapy significantly increased the mean 
values of measured conduction velocities and amplitudes 
in parallel with a significant reduction in the mean values 
of TRCNSS. These benefits of PEMT are supported by a 
study by Lei et al.15 They found that PEMT restores nerve 
abnormalities in treated rats with induced DPN. Also, 
some authors reported that PEMT has direct therapeutic 
effects on injured nerves and it has a hypoglycemic effect 
which may explain the relief of DPN.15,30 The underlying 
mechanisms for these positive effects of PEMT may be 
due to the fact that it modifies peripheral nerve functions, 
increases microvascular blood flow,13,30 accelerates nerve 
conduction velocity,17 and increases the compound action 
Table 3. Post Hoc Test Comparison Among the 3 Treatment Groups
Variables Groups Mean Differences  Standard Error 95% CI P ValueUpper Lower
MCV m/s
Magnetic & drug 3.2 0.97 5.15 1.25 0.002*
Laser & drug 2.69 0.98 4.66 0.73 0.008*
Magnetic & laser 0.59 0.92 2.34 -1.33 0.586
M-ampl mv
Magnetic & drug 0.25 0.12 0.48 0.01 0.030*
Laser & drug 0.27 0.11 0.51 0.04 0.023*
Magnetic & laser -0.01 0.11 0.27 0.26 0.892
SCV m/s
Magnetic & drug 4.58 2.06 8.71 0.46 0.030*
Laser & drug 4.68 2.08 8.84 0.51 0.028*
Magnetic & laser -0.09 1.95 3.79 -3.98 0.961
S-ampl µv
Magnetic & drug 2.45 1.15 4.65 0.26 0.029*
Laser & drug 2.46 1.11 4.68 0.24 0.030*
Magnetic & laser -0.01 1.04 2.06 -2.07 0.993
TRCNSS
Magnetic & drug -0.68 0.14 -0.39 -0.96 0.000*
Laser & drug - 0.75 0.14 -0. 47 - 1.04 0.000*
Magnetic & laser 0.07 0.13 0.34 - 0.19 0.571
VAS
Magnetic & drug -0.22 0.16 0.09 -0.53 0.169
Laser & drug -0.21 0.16 0.11 -0.53 0.191
Magnetic & laser -0.01 0.15 0.29 -0.31 0.951
MCV m/s, Motor condition velocity in meter per second; M-ampl mv, Motor amplitude in millivolt; SCV m/s, Sensory conduction velocity in meter/second; 
S-ampl µv, Sensory amplitudes in microvolt; VAS, visual analog scale; TRCNSS, Toronto Clinical Neuropath Scoring System. 




























Figure 5. Mean Values of the Visual Analog Scale of the 3 Groups. 
potential of peripheral nerves.31 Moreover, PEMT has 
an anti-inflammatory effect accompanied by pain relief. 
It reverses the damage of the peripheral neuropathy and 
finally restores normal conduction velocity.16 In contrast 
to the current results,14,18 they did not recommend the 
usage of PEMT for the treatment of DPN because they 
failed to demonstrate any significant positive effects 
on those patients with DPN. Also, other authors found 
that PEMF did not induce any significant reduction in 
neuropathic pain.32,33 These contradictions between the 
previous studies and the current results may be due to the 
differences in applied parameters, the qualifications of 
magnetic equipment, and the used techniques of PEMF. 
The results of the current study also revealed significant 
improvements in conduction velocities, amplitudes and 
TRCNSS in patients with DPN after treating with LLLT 
in combination with drug therapy. These results were 
supported by some recent studies.4,22,24,25,27 They have 
reported that LLLT is a clinically safe therapy for DPN.24,25 
Some authors stated that LLLT was effective in nerve 
protection and repair with different damage degrees.4,22,24,27 
Other authors have postulated that LLLT can effectively 
reduce DPN, increase MCV, SCV, neural amplitudes, and 
increase microcirculation in patients with DPN.3,22,27 The 
underlying mechanisms of these induced improvements 
by LLLT may be due to the fact that it improves tissue 
perfusion and microcirculation of the ischemic area, has 
an anti-inflammatory effect on the site of injury through 
the reduction of prostaglandin synthesis, increases 
lymphatic flow, decreases local edema, and improves 
neurological functions.19,34 Laser therapy can also allow 
higher neural metabolism and increase myelination and 
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axon regeneration.35 It increases adenosine triphosphate 
synthesis and both serotonin and endorphins secretions.22 
The combined effects of all these various mechanisms 
can justify the induced positive effects of LLLT on the 
pathogenesis of DPN. 24 
In contrast to the current results, Bril et al14 
recommended that LLLT cannot be used as a treatment 
modality for DPN. Also, Zinman et al26 did not support 
its usage in DPN because they did not find any sufficient 
evidence for the usage of LLLT in painful DPN. The 
different laser responses might be due to the differences 
in the intervention time adopted in the 2 studies.21 They 
found LILT has non-significant influences on MCV and 
SCV values in patients with painful DPN. The LLLT 
parameters used in the current study are completely 
different from those applied in a study by Peric and 
Cvetkovic.21 They applied laser therapy for one minute/
site on nine points, while in the current study the target 
areas were the plantar surface of the feet and the lumbo-
sacral area. Each one was exposed for 15 minutes 2 times 
per week for 3 months. In addition, the patients received 
laser therapy only without proper medical control in Peric 
and Cvetkovic,21 whereas in the current study, the patients 
received laser therapy combined with proper analgesic 
medications. The proper parameters of laser application 
are still controversial in the literature, and consequently 
high scientific rigor is needed to define the optimum LLLT 
protocol which is specific in the treatment of DPN.20 There 
are numerous factors can influence the effects of LLLT 
such as the type of laser, radiation characteristics, the type 
of underlying pathology, and treatment regimens such as 
specific type of laser radiation can have different results 
on different pathologies.24 Consequently, more studies 
may be needed prior to generalizing these results.36,37 
This study also revealed a significant reduction in the 
VAS score in the 3 treated groups with non-significant 
differences among them. It means that proper medical 
treatment alone or in addition to magnetic or laser 
interventions can achieve satisfactory analgesic effects 
for patients with DPN.4,11,27 Thus analgesic medications 
are still the most commonly used option to manage 
DPN. These drugs can achieve the analgesic effects for 
neuropathic pain with wide variability depending upon 
the used drugs and the extent of underlying neuropathic 
pathology changes.11,23 In addition, in the long run, the 
required analgesic doses of those patients who will be 
exposed to magnetic or laser therapy will be less because 
of extra positive changes in underlying neuropathic 
pathology. The TRCNSS reduced significantly after 
adding either magnetic or laser therapy to drug therapy, 
but non-significant reductions were obtained in those 
patients who received only drug therapy. This may be 
due to the fact that TRCNSS includes a pain measure in 
addition to other parameters such as touch sensation, 
tendon reflexes and vibration sense which improved 
significantly in those patients exposed to both magnetic 
and laser therapy because of the achievements of other 
physiological advantages in addition to the effectiveness 
of drug therapy. 
Unfortunately, the results of the current study did not 
find any significant differences between the effects of 
adding either magnetic therapy or laser therapy to drug 
therapy in patients with DPN. To the best of investigators’ 
knowledge, no previous study compared both magnetic 
therapy and laser therapy combined with analgesic 
medications.
Conclusion
It was concluded that the addition of either magnetic or 
laser therapy to analgesic medications could bring extra 
positive therapeutic benefits to patients with DPN. There 
were non-significant differences between the effect of 
both magnetic and laser therapy on DPN. Both magnetic 
and laser therapy can be applied in combination with 
analgesic medications as therapeutic modalities for the 
treatment of patients with DPN.
Limitations
Small sample size, evaluation with measurements taken 
only before and after treatment without long-term 
follow-up.
Recommendations
Further studies are needed to compare the effects of 
different intensities of laser and magnetic on DPN using 
a larger sample size for a longer time and with long-term 
follow up. 
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